New Drug Approvals
1 | Marzulene S Combination Granules | Gastritis, Gastric ulcer, duodenal ulcer therapeutic agent (1968:Japan, 1990:China, 2000:India) “Granule mass-production technology” | |||
Marzulene Combination Tablets 1.0ES | (Dosage form addition, 2003:Japan) | ||||
Marzulene Combination Tablets 0.5ES | (Dosage form addition, 2008:Japan) | ||||
Marzulene Combination Tablets 0.375ES | (Dosage form addition, 2009:Japan) | ||||
2 | AZULOXAⓇ Granules 2.5% | Gastric ulcer therapeutic agent (2001:Japan, 2004:Korea) | |||
AZULOXAⓇ Tablets 15mg | (Dosage form addition, 2011:Japan) | ||||
3 | SuglatⓇ Tablets 25mg/50mg (Ipragliflozin (ASP1941) ) | Diabetes therapeutic agent/Selective SGLT2 Inhibitor (Type 2 Diabetes, 2014:Japan, 2015:Korea, 2019:Russia, Joint development with Astellas Pharma Inc.) (Type 1 Diabetes, 2018:Japan, Joint development with Astellas Pharma Inc.) | |||
4 | SUJANUⓇ Combination Tablets (Ipragliflozin/Sitagliptin (MK-0431J) ) | Type 2 Diabetes therapeutic agent/Selective DPP-4 inhibitor/Selective SGLT2 Inhibitor (2018:Japan, Joint development with Astellas Pharma Inc and MSD.) | |||
5 | XOSPATAⓇ Tablets 40mg (giliteritinib (ASP2215) ) | Antineoplastic drug/FLT3 Mutation (2018:Japan/US, 2019:Europe/Canada, 2020:Taiwan/Korea/Brazil/Australia, 2021:China/Singapore, Joint development with Astellas Pharma Inc.) |
R&D Pipeline(2025.4)
1 | ASP1570 | ①Development stage:Global/Phase Ⅰ ②Target:Cancer ③Development:Astellas | ||
2 | ASP2215 (giliteritinib) | ①Development stage:Global/Phase Ⅲ ②Target:Acute myeloid leukemia ③Development:Astellas | ||
3 | S-556971(KT6-971) | ①Development stage:Japan/Phase Ⅱ, Europe/Phase I ②Target:Dyslipidemia ③Development:Kotobuki | ||
4 | KT7-533: α-C-Galactosyl Ceramide | (Phase I in preparation:licensing-out) |
Medicinal Chemistry
Azulene Chemistry; Carbohydrate Chemistry; Transporter Inhibitor; Kinase Inhibitor;
Enzyme Inhibitor; Receptor Antagonist; Protein-Protein Interaction Inhibitor; Immunity
Pharmaceutical Engineering
Combination Granule; Combination Tablet; Easy to Swallow Tablet; Easy to Split with fingers Tablet;
Bitterness Reduction Technology; Miniaturized Tablet; Film-Coated Orally Disintegrating Tablet


